Drug Profile
Research programme: EGFR/HER2 inhibitors - Allist Pharmaceuticals
Alternative Names: ALL-3; AST-6Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Allist Pharmaceuticals
- Class Quinazolines
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China
- 19 Nov 2009 Preclinical trials in Cancer in China (unspecified route)